Adbry

(tralokinumab)
Adbry 150 MG/ML in 1 ML Prefilled Syringe
NO BOXED WARNING

Dosage & administration

drug label

Adbry prescribing information

prior authorization

Adbry prior authorization resources

Most recent Adbry prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Request
Coverage Authorization Appeals
Letter of Medical Exception
Learn More

Benefits investigation

Adbry Advocate Enrollment Form
Adbry Advocate Enrollment Form - Spanish
Learn More

financial assistance

Adbry financial assistance options

Co-pay savings program

commercial only
Adbry Advocate Enrollment Form
Adbry Advocate Enrollment Form - Spanish
Enroll in Patient Savings Program
Learn More

Bridge program

commercial only
Adbry Advocate Enrollment Form
Adbry Advocate Enrollment Form - Spanish
Bridge Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Adbry Advocate Enrollment Form
Adbry Advocate Enrollment Form - Spanish
Adbry Patient Assistance Program
Learn More

PubMed™ | Adbry

Adbry PubMed™ News

patient education

Adbry patient education

Getting started on Adbry

Instructions For Use: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Adbry
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Adbry
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

Other resources

App Download - iOS
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
App Download - Android
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Adbry FAQs

Is ADBRY safe to use during pregnancy?There is limited data on the use of ADBRY in pregnant women to determine if there is a drug-associated risk of adverse developmental outcomes. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in a pregnancy exposure registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/. Human IgG antibodies, such as those in ADBRY, are known to cross the placental barrier; therefore, ADBRY may be transmitted from the mother to the developing fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown, and all pregnancies have a background risk of adverse outcomes.
Has ADBRY been tested in animals for pregnancy and developmental effects?In animal studies, intravenous doses of up to 100 mg/kg tralokinumab-ldrm were administered to pregnant cynomolgus monkeys without observing any maternal or developmental toxicity at doses up to 100 mg/kg/week. No treatment-related adverse effects on embryofetal toxicity or malformations, or on morphological, functional, or immunological development were observed in the infants from birth through 6 months of age in another enhanced pre- and post-natal development study.
Is it safe to use ADBRY while breastfeeding?There is no data on the presence of tralokinumab-ldrm in human milk or its effects on breastfed infants or milk production. Maternal IgG is present in breast milk, and the effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown. Healthcare providers should consider the development and health benefits of breastfeeding along with the mother's clinical need for ADBRY and any potential adverse effects on the breastfed child from ADBRY or from the underlying maternal condition.
Is ADBRY safe for use in pediatric patients?The safety and effectiveness of ADBRY have not been established in pediatric patients.
Is ADBRY safe for use in geriatric patients?Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Healthcare providers should exercise caution in dose selection for elderly patients, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
FAQ Data Source